FDA Finalizes Guidance on Accelerated Approval of Early Breast Cancer Trials

Drug Industry Daily
Drugmakers seeking accelerated approval of a presurgical treatment for high-risk, early-stage breast cancer may consider conducting multiple trials rather than a traditional single trial, according to a new FDA guidance that aims to give sponsors an earlier indication as to the success of a drug candidate.

To View This Article:


Subscribe To Drug Industry Daily